Viveve Submits Investigational Device Exemption to FDA to Conduct LIBERATE-U.S. Trial for Improvement of Stress Urinary Incontinence
Viveve Medical (NASDAQ:VIVE), a medical technology company focused on women’s intimate health, today announced submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) for authorization to begin LIBERATE-U.S., a multicenter, randomized, double-blinded, sham-controlled trial to evaluate the safety and efficacy of the Company’s proprietary, cryogen-cooled monopolar radiofrequency (CMRF) technology …
Viveve Medical (NASDAQ:VIVE), a medical technology company focused on women’s intimate health, today announced submission of an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) for authorization to begin LIBERATE-U.S., a multicenter, randomized, double-blinded, sham-controlled trial to evaluate the safety and efficacy of the Company’s proprietary, cryogen-cooled monopolar radiofrequency (CMRF) technology for the improvement of stress urinary incontinence (SUI) in women.
As quoted in the press release:
“The IDE submission for approval to conduct the LIBERATE-U.S. trial is an important milestone towards our objective to obtain regulatory clearances for CMRF for the treatment of SUI, a condition that we estimate affects approximately 25-30 million women worldwide,” stated Scott Durbin, chief executive officer and director of Viveve. “This trial is also another reflection of our commitment to conducting sound scientific research and rigorous clinical trials that support the highest levels of evidence-based medicine to deliver safe and effective treatment of women’s intimate health conditions using our proprietary CMRF technology. Pending authorization to proceed with the LIBERATE-U.S. trial, Viveve will have two ongoing multicenter SUI registration studies underway including our LIBERATE-International trial initiated in Canada in August 2018.”
MARKETS
COMMODITIES
Commodities | |||
---|---|---|---|
Gold | 1854.99 | +0.90 | |
Silver | 21.54 | +0.01 | |
Copper | 4.21 | 0.00 | |
Palladium | 2025.50 | +4.50 | |
Platinum | 996.00 | +4.50 | |
Oil | 105.11 | -0.60 | |
Heating Oil | 3.75 | 0.00 | |
Natural Gas | 7.44 | -0.20 |
DOWNLOAD FREE REPORTS
BROWSE COMPANIES BY SECTOR
- Agriculture Investing
- Phosphate Investing
- Potash Investing
- Base Metals Investing
- Copper Investing
- Iron Investing
- Lead Investing
- Nickel Investing
- Zinc Investing
- Battery Metals Investing
- Cobalt Investing
- Graphite Investing
- Lithium Investing
- Manganese Investing
- Vanadium Investing
- Critical Metals Investing
- Magnesium Investing
- Rare Earth Investing
- Scandium Investing
- Tantalum Investing
- Tellurium Investing
- Tungsten Investing
- Energy Investing
- Oil and Gas Investing
- Uranium Investing
- Gem Investing
- Diamond Investing
- Industrial Metals Investing
- Aluminum Investing
- Chromium Investing
- Coal Investing
- Molybdenum Investing
- Tin Investing
- Precious Metals Investing
- Gold Investing
- Palladium Investing
- Platinum Investing
- Silver Investing
- 3D Printing Investing
- Bitcoin Investing
- Blockchain Investing
- Cleantech Investing
- Cloud Investing
- Cryptocurrencies
- Data Investing
- Emerging Tech Investing
- Artificial Intelligence Investing
- Mobile Investing
- Robotics Investing
- Fintech Investing
- Gaming Investing
- Esports Investing
- Nanoscience Investing
- Graphene Investing
- Nanotech Investing
- Security Investing
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.